The curious case of Wuhan’s Institute of Virology and remdesivir
Changes to China’s patent laws and a filing by a Wuhan lab involving Gilead’s remdesivir have set up an interesting patent race, says Thomas Moga of Dykema.
Latest news
France backs COVID-19 vaccine IP waiver
14-06-2021
French President Emmanuel Macron has committed to backing the proposal to waive IP rights for COVID-19 vaccines ahead of the G7 Summit taking place in England this weekend.
